The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Association between Initial Treatment Strategy and Long-Term Survival in Pulmonary Arterial Hypertension
Abstract
Abstract Rationale The relationship between the initial treatment strategy and survival in pulmonary arterial hypertension (PAH) remains uncertain. Objectives To evaluate the long-term survival of patients with PAH categorized according to the initial treatment strategy. Methods A retrospective analysis of incident patients with idiopathic, heritable, or anorexigen-induced PAH enrolled in the French Pulmonary Hypertension Registry (January 2006 to December 2018) was conducted. Survival was assessed according to the initial strategy: monotherapy, dual therapy, or triple-combination therapy (two oral medications and a parenteral prostacyclin). Measurements and Main Results Among 1,611 enrolled patients, 984 were initiated on monotherapy, 551 were initiated on dual therapy, and 76 were initiated on triple therapy. The triple-combination group was younger and had fewer comorbidities but had a higher mortality risk. The survival rate was higher with the use of triple therapy (91% at 5 yr) as compared with dual therapy or monotherapy (both 61% at 5 yr) (P < 0.001). Propensity score matching of age, sex, and pulmonary vascular resistance also showed significant differences between triple therapy and dual therapy (10-yr survival, 85% vs. 65%). In high-risk patients (n = 243), the survival rate was higher with triple therapy than with monotherapy or dual therapy, whereas there was no difference between monotherapy and double therapy. In intermediate-risk patients (n = 1,134), survival improved with an increasing number of therapies. In multivariable Cox regression, triple therapy was independently associated with a lower risk of death (hazard ratio, 0.29; 95% confidence interval, 0.11–0.80; P = 0.017). Among the 148 patients initiated on a parenteral prostacyclin, those on triple therapy had a higher survival rate than those on monotherapy or dual therapy. Conclusions Initial triple-combination therapy that includes parenteral prostacyclin seems to be associated with a higher survival rate in PAH, particularly in the youngest high-risk patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Galiè, N., Humbert, M., Vachiery, J.-L., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Vonk Noordegraaf, A., Beghetti, M., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv317 · Cited by 6,931
Self-citationPredicting Survival in Patients With Pulmonary Arterial Hypertension
Benza, R. L., Gomberg-Maitland, M., Elliott, C. G., Farber, H. W., Foreman, A. J., Frost, A. E., McGoon, M. D., Pasta, D. J., Selej, M., Burger, C. D., et al. (2019) · Chest · doi:10.1016/j.chest.2019.02.004 · Cited by 643
Cited by
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Humbert, M., Kovacs, G., Hoeper, M. M., Badagliacca, R., Berger, R. M. F., Brida, M., Carlsen, J., Coats, A. J. S., Escribano-Subias, P., Ferrari, P., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac237 · Cited by 3,975
Self-citation2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Humbert, M., Kovacs, G., Hoeper, M. M., Badagliacca, R., Berger, R. M. F., Brida, M., Carlsen, J., Coats, A. J. S., Escribano-Subias, P., Ferrari, P., et al. (2023) · European Respiratory Journal · doi:10.1183/13993003.00879-2022 · Cited by 2,247
Self-citationCOMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension
Hoeper, M. M., Pausch, C., Olsson, K. M., Huscher, D., Pittrow, D., Grünig, E., Staehler, G., Vizza, C. D., Gall, H., Distler, O., et al. (2022) · European Respiratory Journal · doi:10.1183/13993003.02311-2021 · Cited by 349
Insights into bone morphogenetic proteins in cardiovascular diseases
Ye, D., Liu, Y., Pan, H., Feng, Y., Lu, X., Gan, L., Wan, J., & Ye, J. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1125642 · Cited by 37
Self-citation
Metadata
- Authors
- Boucly, A., Savale, L., Jaïs, X., Bauer, F., Bergot, E., Bertoletti, L., Beurnier, A., Bourdin, A., Bouvaist, H., Bulifon, S., Chabanne, C., Chaouat, A., Cottin, V., Dauphin, C., Degano, B., De Groote, P., Favrolt, N., Feng, Y., Horeau-Langlard, D., Jevnikar, M., Jutant, E.-M., Liang, Z., Magro, P., Mauran, P., Moceri, P., Mornex, J.-F., Palat, S., Parent, F., Picard, F., Pichon, J., Poubeau, P., Prévot, G., Renard, S., Reynaud-Gaubert, M., Riou, M., Roblot, P., Sanchez, O., Seferian, A., Tromeur, C., Weatherald, J., Simonneau, G., Montani, D., Humbert, M., & Sitbon, O.
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2021-10-01
- Volume
- 204
- Issue
- 7
- Pages
- 842-854
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- OpenAlex
- W3174814045
- Cited by
- 204
- References
- 2
- FWCI
- 19.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Association between Initial Treatment Strategy and Long-Term Survival in Pulmonary Arterial Hypertension. https://app.cochat.ai/papers/10.1164/rccm.202009-3698oc
- The paper
- Boucly, A., Savale, L., Jaïs, X., Bauer, F., Bergot, E., Bertoletti, L., Beurnier, A., Bourdin, A., Bouvaist, H., Bulifon, S., Chabanne, C., Chaouat, A., Cottin, V., Dauphin, C., Degano, B., De Groote, P., Favrolt, N., Feng, Y., Horeau-Langlard, D., . . . Sitbon, O. (2021). Association between Initial Treatment Strategy and Long-Term Survival in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/rccm.202009-3698oc
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.